Showing results for fx-322
Search instead for DX-322
🌐
Clinicaltrials
classic.clinicaltrials.gov › ct2 › show › NCT05086276
NCT05086276
Study record managers: refer to the Data Element Definitions if submitting registration or results information
🌐
Healthy Hearing
healthyhearing.com › home › report › experimental hearing loss drug fails to show benefit in clinical trial
Hearing loss drug FX-322 fails to show benefit in clinical trials
February 15, 2023 - Frequency Therapeutics halted its clinical trial for the experimental hearing loss drug FX-322 due to disappointing clinical trials results.
🌐
BioSpace
biospace.com › frequency-therapeutics-announces-topline-results-for-its-phase-2b-study-of-fx-322-for-the-treatment-of-sensorineural-hearing-loss
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss - BioSpace
February 13, 2023 - Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired…
🌐
NCBI
ncbi.nlm.nih.gov › pmc › articles › PMC8279894
Improved Speech Intelligibility in Subjects With Stable Sensorineural Hearing Loss Following Intratympanic Dosing of FX-322 in a Phase 1b Study - PMC
There are no approved pharmacologic therapies for chronic sensorineural hearing loss (SNHL). The combination of CHIR99021+valproic acid (CV, FX-322) has been shown to regenerate mammalian cochlear hair cells ex vivo. The objectives were to characterize ...
🌐
Hearing Aid UK
hearingaid.org.uk › flash-audiology-news › could-the-fx322-drug-cure-hearing-loss
Could the FX 322 drug cure hearing loss? | Hearing Aid UK
04:10
The FX 322 gel is said to reverse hearing loss. Let's take a look at the science & facts behind this new drug for hearing loss. Is this really a cure?
Published: July 18, 2023
🌐
Springer
adisinsight.springer.com › drugs › 800050002
FX 322 - AdisInsight
January 11, 2024 - FX 322 is a small molecule drug, being developed by Frequency Therapeutics, for the treatment of sensorineural hearing loss (SNHL). FX 322 has been formulated
🌐
HearingTracker
hearingtracker.com › home › news › frequency therapeutics abandons hearing loss drug development
Frequency Therapeutics Abandons Hearing Loss Treatment Programs
February 13, 2023 - Frequency Therapeutics Inc. has announced the cessation of its FX-322 and FX-345 programs designed to help people with sudden or noise-induced sensorineural hearing loss (SNHL) only a few months after biotech hearing loss developer Otonomy closed its doors. What does this mean for people with ...
🌐
Nasdaq
nasdaq.com › articles › frequency-therapeutics-to-discontinue-fx-322-development-program-to-immediately-reduce
Frequency Therapeutics To Discontinue FX-322 Development Program; To Immediately Reduce Headcount | Nasdaq
February 13, 2023 - (RTTNews) - Frequency Therapeutics, Inc. (FREQ) reported clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss. The study failed to achieve its primary efficacy endpoint of an improvement in speech perception
🌐
PubMed
pubmed.ncbi.nlm.nih.gov › 33617194
Improved Speech Intelligibility in Subjects With Stable Sensorineural Hearing Loss Following Intratympanic Dosing of FX-322 in a Phase 1b Study - PubMed
Delivery of FX-322 to the extended high-frequency region of the cochlea is well tolerated and enhances speech recognition performance in multiple subjects with stable chronic hearing loss.
🌐
LWW
journals.lww.com › otology-neurotology › fulltext › 2021 › 08000 › improved_speech_intelligibility_in_subjects_with.14.aspx
Improved Speech Intelligibility in Subjects With Stable... : Otology & Neurotology
profile of CV in guinea pigs, then measure FX-322 in human perilymph samples, and finally assess safety and audiometric effects of FX-322 in humans with chronic SNHL. Study Designs: Middle ear residence, cochlear distribution, and elimination profiles of FX-322 were assessed in guinea pigs.
🌐
Usf
usf.edu › cbcs › csd › labs › arct › research › single-and-repeat-dose-multicenter-exploratory-efficacy-study-of-fx-322-etc.aspx
Sensorineural Hearing Loss Study | ARCT | CSD | USF
Eligibility: Participants must be between 18-65 years old with an established diagnosis of stable sensorineural hearing loss by standard hearing tests. Goal: To evaluate a new investigational medication called FX-322 that is delivered directly in the ear through the eardrum.
🌐
GEN
genengnews.com › home › topics › drug discovery › stockwatch: regeneron’s all ears for hearing loss drug developer
StockWatch: Regeneron’s All Ears for Hearing Loss Drug Developer
August 14, 2023 - Just last month, Korro Bio agreed to combine with Frequency Therapeutics through a reverse merger set to close in the fourth quarter. Frequency’s former lead candidate FX-322 in February failed a Phase IIb trial (FX-322-208; NCT05086276) in patients with acquired sensorineural hearing loss.
🌐
Frequencytx
frequencytx.com › home
Frequency Therapeutics: FX 322 | Regenerative Medicine ...
December 15, 2022 - Pioneering RNA editing to deliver the future of medicine · RNA editing holds great promise to rewrite what’s possible for patients. Since the discovery of the first generation of editing technologies, researchers have been working to overcome the inherent complexity of these initial approaches ...
🌐
Thepharmaletter
thepharmaletter.com › pharmaceutical › frequency-therapeutics-tanks-as-hearing-loss-trial-fails
Frequency Therapeutics tanks as hearing loss trial fails | The Pharmaletter
June 25, 2024 - Shares of US regenerative medicines firm Frequency Therapeutics (Nasdaq: FREQ) plummeted more than 80% to $0.75 yesterday, after it announced it is terminating programs in sensorineural hearing loss (SNHL) because FX-322 failed to meet the goal of a study in people with acquired SNHL, and is ...
🌐
Clinicaltrials
clinicaltrials.gov › study › NCT05086276
ClinicalTrials.gov
October 20, 2021 - Study record managers: refer to the Data Element Definitions if submitting registration or results information
🌐
Clinicaltrials
clinicaltrials.gov › study › NCT04120116
FX-322 in Adults With Stable Sensorineural Hearing Loss
October 20, 2021 - Study record managers: refer to the Data Element Definitions if submitting registration or results information
🌐
MedCity News
medcitynews.com › home › frequency therapeutics regenerative med for hearing loss fails again in phase 2
Frequency Therapeutics Regenerative Med for Hearing Loss Fails Again in Phase 2 - MedCity News
April 3, 2024 - Frequency was testing its hearing loss therapy, FX-322, in patients who have sensorineural hearing loss (SNHL), which is caused by damage to the tiny hair cells in the ear that turn vibrations into the electrical signals sent to the brain via the auditory nerve.